Incidence and spectrum of immune-related adverse events in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors

Key Points

• Immune-related adverse events occur frequently in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors, highlighting treatment risks.
• The study identifies a spectrum of immune-related adverse events, including skin reactions and endocrine disorders, affecting overall patient management.
• Analysis of clinical data from nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors reveals critical insights into adverse events.
• These findings emphasize the importance of monitoring immune-related adverse events, particularly due to potential for serious complications during treatment.